secwatch.observer — SEC 8-K summary
======================================

Issuer:     Milestone Pharmaceuticals Inc. (MIST)
CIK:        0001408443
Form:       8-K
Filed at:   2022-03-24T23:59:59+00:00
Accession:  0001104659-22-037283
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Milestone Pharma reports FY2021 net loss of $42.9M; revenue of $15M from collaboration
--------------------------------------------------------------------------------

- Net loss for FY2021 was $42.9M ($1.02 loss per share) vs $50.0M ($1.70 loss per share) in FY2020.
- Revenue of $15.0M recognized in 2021 from collaboration agreement; no revenue in 2020.
- R&D expenses $38.7M, G&A $12.4M, commercial $7.0M in FY2021.
- Cash and cash equivalents $114.1M at Dec 31, 2021, down from $142.3M (incl short-term investments) at Dec 31, 2020.
- Accumulated deficit reached $206.3M as of Dec 31, 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1408443/000110465922037283/0001104659-22-037283-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1408443/000110465922037283/tm2210321d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-037283

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer